{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T12:17:55Z","timestamp":1764332275980},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1097\/hrp.0000000000000025","type":"journal-article","created":{"date-parts":[[2014,11,6]],"date-time":"2014-11-06T05:24:50Z","timestamp":1415251490000},"page":"367-372","source":"Crossref","is-referenced-by-count":24,"title":["Critical Issues on the Use of Network Meta-analysis in Psychiatry"],"prefix":"10.1097","volume":"22","author":[{"given":"Ay\u015feg\u00fcl","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph U.","family":"Correll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mateusz","family":"Nikodem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross J.","family":"Baldessarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-11-20210129","doi-asserted-by":"crossref","first-page":"b1147","DOI":"10.1136\/bmj.b1147","article-title":"Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews.","volume":"338","author":"Song","year":"2009","journal-title":"BMJ"},{"key":"R3-11-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00019053-200624010-00001","article-title":"Bayesian methods for evidence synthesis in cost-effectiveness analysis.","volume":"24","author":"Ades","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"R4-11-20210129","doi-asserted-by":"crossref","first-page":"3105","DOI":"10.1002\/sim.1875","article-title":"Combination of direct and indirect evidence in mixed treatment comparisons.","volume":"23","author":"Lu","year":"2004","journal-title":"Stat Med"},{"key":"R5-11-20210129","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: combining direct and indirect evidence.","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"R6-11-20210129","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis.","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"R7-11-20210129","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jclinepi.2008.10.001","article-title":"Case study of multiple-treatments meta-analysis demonstrates that covariates should be considered.","volume":"62","author":"Salanti","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R8-11-20210129","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/1741-7015-11-159","article-title":"Is network meta-analysis as valid as standard pairwise meta-analysis It all depends on the distribution of effect modifiers.","volume":"11","author":"Jansen","year":"2013","journal-title":"BMC Med"},{"key":"R9-11-20210129","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/0962280207080643","article-title":"Evaluation of networks of randomized trials.","volume":"17","author":"Salanti","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"R10-11-20210129","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(13)61032-6","article-title":"Antipsychotics for acute schizophrenia: making choices.","volume":"382","author":"Correll","year":"2013","journal-title":"Lancet"},{"key":"R11-11-20210129","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1017\/S146114571100040X","article-title":"Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study.","volume":"14","author":"Vieta","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R12-11-20210129","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1198\/016214505000001302","article-title":"Assessing evidence inconsistency in mixed treatment comparisons.","volume":"101","author":"Lu","year":"2006","journal-title":"J Am Statist Assoc"},{"key":"R13-11-20210129","doi-asserted-by":"crossref","first-page":"734","DOI":"10.7326\/0003-4819-149-10-200811180-00008","article-title":"Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.","volume":"149","author":"Gartlehner","year":"2008","journal-title":"Ann Intern Med"},{"key":"R14-11-20210129","doi-asserted-by":"crossref","first-page":"772","DOI":"10.7326\/0003-4819-155-11-201112060-00009","article-title":"Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.","volume":"155","author":"Gartlehner","year":"2011","journal-title":"Ann Intern Med"},{"key":"R15-11-20210129","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/S0140-6736(09)60046-5","article-title":"Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis.","volume":"373","author":"Cipriani","year":"2009","journal-title":"Lancet"},{"key":"R16-11-20210129","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S0140-6736(11)60873-8","article-title":"Comparative efficacy and acceptability of antimanic drugs in acute mania: multiple-treatments meta-analysis.","volume":"378","author":"Cipriani","year":"2011","journal-title":"Lancet"},{"key":"R17-11-20210129","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3109\/07853890.2012.705016","article-title":"Comparisons of high-dose and combination nicotine replacement therapy, varenicline, and bupropion for smoking cessation: a systematic review and multiple treatment meta-analysis.","volume":"44","author":"Mills","year":"2012","journal-title":"Ann Med"},{"key":"R18-11-20210129","doi-asserted-by":"crossref","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","article-title":"Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis.","volume":"157","author":"Hartling","year":"2012","journal-title":"Ann Intern Med"},{"key":"R19-11-20210129","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"R21-11-20210129","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1192\/bjp.182.2.141","article-title":"Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial.","volume":"182","author":"Yatham","year":"2003","journal-title":"Br J Psychiatry"},{"key":"R22-11-20210129","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1176\/appi.ajp.159.7.1146","article-title":"Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.","volume":"159","author":"Sachs","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R23-11-20210129","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1017\/S1461145710001641","article-title":"Factors modifying drug and placebo responses in randomized trials for acute mania.","volume":"14","author":"Yildiz","year":"2011","journal-title":"Int J Neuropsychopharmacol"},{"key":"R24-11-20210129","first-page":"97","article-title":"Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling.","volume":"24","author":"Overall","year":"1988","journal-title":"Psychopharmacol Bull"},{"key":"R25-11-20210129","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"Rating scale for mania: reliability, validity and sensitivity.","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"R26-11-20210129","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/npp.2010.192","article-title":"Efficacy of antimanic treatments: meta-analysis of randomized controlled trials.","volume":"36","author":"Yildiz","year":"2011","journal-title":"Neuropsychopharmacology"},{"key":"R27-11-20210129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial.","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"R28-11-20210129","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics.","volume":"163","author":"Heres","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R29-11-20210129","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1176\/appi.ajp.159.6.1011","article-title":"Olanzapine vs. divalproex in the treatment of acute mania.","volume":"159","author":"Tohen","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R30-11-20210129","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.4088\/JCP.v63n1210","article-title":"Comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder.","volume":"63","author":"Zajecka","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R31-11-20210129","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.euroneuro.2011.11.011","article-title":"Head to head comparisons as an alternative to placebo-controlled trials.","volume":"22","author":"Vieta","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"R32-11-20210129","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1001\/jama.289.19.2534","article-title":"Health outcomes associated with various antihypertensive therapies used as first-line agents. A network meta-analysis.","volume":"289","author":"Psaty","year":"2003","journal-title":"JAMA"}],"container-title":["Harvard Review of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HRP.0000000000000025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:44:23Z","timestamp":1620953063000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00023727-201411000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/hrp.0000000000000025","relation":{},"ISSN":["1067-3229"],"issn-type":[{"value":"1067-3229","type":"print"}],"subject":[],"published":{"date-parts":[[2014,11]]}}}